Education
About Us
Working with TipRanks
Follow Us
PharmaNutra SpA (IT:PHN)
:PHN
PHN Stock Chart & Stats
€75.40
-€0.80(-1.51%)
At close: 4:00 PM EST
€75.40
-€0.80(-1.51%)
Day’s Range― - ―
52-Week Range€38.75 - €76.70
Previous CloseN/A
Volume2.81K
Average Volume (3M)25.97K
Market Cap
€729.95M
Enterprise Value€725.09M
Total Cash (Recent Filing)€30.61M
Total Debt (Recent Filing)€20.51M
Price to Earnings (P/E)26.0
Beta0.36
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.86%
Share Statistics
EPS (TTM)0.62
Shares Outstanding9,680,977
10 Day Avg. Volume12,507
30 Day Avg. Volume25,966
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)7.28
Price to Sales (P/S)3.95
P/FCF Ratio31.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€82.67Price Target Upside9.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)2.48
Revenue Forecast (FY)€151.99M
Bulls Say, Bears Say
Bulls Say
Analyst Sentiment And ValuationAnalyst's recommendation is Buy and the stock is viewed as offering meaningful upside because valuation multiples trade below historical averages, suggesting potential re-rating with successful execution.
Research And DevelopmentStrong commitment to research and development with multiple planned product launches and an extensive pre-clinical pipeline increases prospects for future revenue diversification and long-term growth.
US E-commerce TractionSiderAL's rising position on Amazon USA and a higher buyer-count label signal improving consumer traction on the e-commerce channel, supporting revenue growth and scale toward operating break-even in the US.
Bears Say
Margin PressureOngoing investments in new ventures are likely to put temporary pressure on margins, weighing on near-term profitability.
Operating Expense TrajectoryHigher operating expenses related to new initiatives could delay the pace at which the business reaches sustained operating break-even.
Working Capital And Cash FlowOngoing investments may increase working capital absorption and limit free cash flow, constraining financial flexibility during the investment phase.
PharmaNutra SpA News
PHN FAQ
What was PharmaNutra SpA’s price range in the past 12 months?
PharmaNutra SpA lowest stock price was €38.75 and its highest was €76.70 in the past 12 months.
What is PharmaNutra SpA’s market cap?
PharmaNutra SpA’s market cap is €729.95M.
When is PharmaNutra SpA’s upcoming earnings report date?
PharmaNutra SpA’s upcoming earnings report date is May 11, 2026 which is in 48 days.
How were PharmaNutra SpA’s earnings last quarter?
PharmaNutra SpA released its earnings results on Mar 17, 2026. The company reported €0.62 earnings per share for the quarter, the consensus estimate of €0.62 by €0.
Is PharmaNutra SpA overvalued?
According to Wall Street analysts PharmaNutra SpA’s price is currently Undervalued.
Does PharmaNutra SpA pay dividends?
PharmaNutra SpA pays a Annually dividend of €1 which represents an annual dividend yield of 1.86%. See more information on PharmaNutra SpA dividends here
What is PharmaNutra SpA’s EPS estimate?
PharmaNutra SpA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaNutra SpA have?
PharmaNutra SpA has 9,680,977 shares outstanding.
What happened to PharmaNutra SpA’s price movement after its last earnings report?
PharmaNutra SpA reported an EPS of €0.62 in its last earnings report, expectations of €0.62. Following the earnings report the stock price went up 0.295%.
Which hedge fund is a major shareholder of PharmaNutra SpA?
Currently, no hedge funds are holding shares in IT:PHN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaNutra SpA
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
PHN Stock 12 Month Forecast
Average Price Target
€82.67
▲(9.64% Upside)
Technical Analysis
Philogen SpA
―
Farmacosmo S.P.A.
―
Farmae SpA
―
Laboratorio Farmaceutico Erfo SpA
―
Svas Biosana S.p.A.
―
Options Prices
Currently, No data available
---